



August 4, 2021

Company name Shin Nippon Biomedical Laboratories, Ltd.  
 Representative Representative Chairman, President & CEO  
 Ryoichi Nagata  
 Listing TSE first section: ticker code 2395  
 Inquiries Senior Officer & Senior Director, Corporate Communications  
 Toshiyuki Iwata  
 TEL +81 3 5565 6216

## **Notice Regarding Extraordinary Income and Upward Revision of the Earnings Forecasts for the Six Months of the Fiscal Year Ending March 31, 2022**

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, “the Company”) announces the following extraordinary income recorded during the first three months of the fiscal year ending March 31, 2022, and revision to the forecast of the six months consolidated results for the fiscal year ending March 31, 2022 (from April 1, 2021 to September 30, 2021) announced on May 10, 2021.

### **1. Extraordinary income (gains on sale of shares of subsidiaries and associates and change in equity)**

As announced on April 7, 2021, the Company executed share transfer and third-party allocation of new shares to Pharmaron Beijing Co., Ltd. (“Pharmaron Group”) in relation to Biomedical Research (GZ) Ltd. (“SNBL CHINA”). SNBL CHINA engages in the business of laboratory animal breeding, raising, and quarantine, and the Pharmaron Group is a listed company in China that engages in the business of pharmaceutical R&D services worldwide. As a result, Pharmaron Group now holds 50.01% of the equity in SNBL CHINA. Thus, the extraordinary income of ¥1,360 million (gain on sale of shares of subsidiaries and associates: ¥1,038 million, gain on change in equity: ¥322 million) was posted during the three months of the fiscal year ending March 31, 2022.

### **2. Revision to the forecast of the six months consolidated results for the fiscal year ending March 31, 2022**

(1) Details of the revision to the consolidated financial results forecasts (from April 1, 2021 to June 30, 2021)

	Net Sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecasts (A)	7,455	1,220	1,550	1,540	36.99
Revised forecasts (B)	7,455	1,220	1,550	2,540	61.01
Changes (B - A)	-	-	-	+1,000	
Changes (%)	-	-	-	+64.9	
ref.) Results of the six months of the fiscal year ended March 31, 2021	7,003	1,161	1,305	1,139	27.36

(2) Reasons for the revision to the consolidated financial results forecasts

Due to the posting of the extraordinary income stated above, the profit attributable to owners of parent is expected to exceed the original forecast, while the Company’s full year earnings forecasts for the same fiscal year remains unchanged.

(NOTE) Financial forecasts and other statements above are based on information available as of the date of this announcement.

Actual performance may differ substantially due to various factors in the future